“SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular Protection from an Oral GLP-1 in High-Risk Type 2 Diabetes”. 2026. Diabzen 4 (19): 38-39. https://thediabzen.com/index.php/d/article/view/62.